GOVX
GeoVax Labs
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 3
consensus rating "Strong Buy"
Bearish Engulfing
EPS Below Expectations
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GOVX
Geovax Labs, Inc.
A clinical-stage biotechnology company that developing immunotherapies and vaccines for cancer and infectious diseases
1900 Lake Park Drive, Suite 380, Smyrna, GA 30080
--
GeoVax Labs, Inc., was established in June 1988. The company is a clinical-stage biotechnology company that develops immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (modified vaccinia Ankara virus-like particles or "GV-MVA-VLPTM "). The company's current development plans focus on preventive and therapeutic vaccines against human immunodeficiency virus (HIV); preventive vaccines against hemorrhagic fever virus (Ebola, Sudan, Marburg and Lhasa), Zika virus and malaria; therapeutic vaccines for chronic hepatitis B virus infection and immunotherapy against solid tumor cancer.
Company Financials
EPS
GOVX has released its 2024 Q3 earnings. EPS was reported at -0.91, versus the expected -1.48, beating expectations. The chart below visualizes how GOVX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GOVX has released its 2024 Q4 earnings report, with revenue of 864.42K, reflecting a YoY change of NaN%, and net profit of -8.26M, showing a YoY change of -8.83%. The Sankey diagram below clearly presents GOVX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
